PHATHOM PHARMACEUTICALS, INC. Financing Cash Flow
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Financing Cash Flow of $70.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.55M, a 4338.75% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $66.64M.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$97.00K, a 100.37% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$271.00K, a 100.22% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was -$288.00K, a 100.16% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $182.77M, a 50.28% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $367.58M, a 206.21% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $120.04M, a 168.50% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $70.19M 10-Q · filed 2026-07-30 | $70.09M derived: sum of 3 quarters · filed 2026-07-30 | $69.82M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $66.64M 10-Q · filed 2026-04-30 | $66.54M derived: sum of 2 quarters · filed 2026-04-30 | $66.27M derived: sum of 3 quarters · filed 2026-04-30 | $66.35M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$368.00K derived: sum of 2 quarters · filed 2026-02-26 | -$288.00K derived: sum of 3 quarters · filed 2026-07-30 | -$288.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$271.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$191.00K derived: sum of 2 quarters · filed 2026-07-30 | -$191.00K 10-Q · filed 2025-10-30 | $25.86M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $80.00K 10-Q · filed 2026-07-30 | $26.13M derived: sum of 3 quarters · filed 2026-07-30 | $148.18M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $26.05M derived: sum of 2 quarters · filed 2026-04-30 | $148.10M derived: sum of 3 quarters · filed 2026-04-30 | $172.87M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $26.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $148.10M derived: sum of 2 quarters · filed 2026-02-26 | $172.87M derived: sum of 3 quarters · filed 2026-02-26 | $182.77M 10-K · filed 2026-02-26 |
| 2024-09-30 | $122.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $146.83M derived: sum of 2 quarters · filed 2025-10-30 | $156.73M 10-Q · filed 2025-10-30 | $368.72M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $24.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $34.67M 10-Q · filed 2025-08-07 | $246.66M derived: sum of 3 quarters · filed 2025-08-07 | $246.68M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.90M 10-Q · filed 2025-05-01 | $221.89M derived: sum of 2 quarters · filed 2025-05-01 | $221.91M derived: sum of 3 quarters · filed 2025-05-01 | $363.41M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $211.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $212.01M derived: sum of 2 quarters · filed 2025-03-06 | $353.51M derived: sum of 3 quarters · filed 2025-03-06 | $367.58M 10-K · filed 2025-03-06 |
| 2023-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $141.51M derived: sum of 2 quarters · filed 2024-11-07 | $155.59M 10-Q · filed 2024-11-07 | $155.59M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $141.50M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $155.57M 10-Q · filed 2024-08-08 | $155.57M derived: sum of 3 quarters · filed 2024-08-08 | $180.17M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $14.07M 10-Q/A · filed 2024-06-14 | $14.07M derived: sum of 2 quarters · filed 2024-06-14 | $38.67M derived: sum of 3 quarters · filed 2024-06-14 | |
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $24.60M derived: sum of 2 quarters · filed 2024-06-14 | $120.04M 10-K/A · filed 2024-06-14 | |
| 2022-09-30 | $24.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $120.04M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $95.45M 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $163.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $44.19M derived: sum of 2 quarters · filed 2023-02-28 | $44.30M derived: sum of 3 quarters · filed 2023-02-28 | $44.71M 10-K · filed 2023-02-28 |
| 2021-09-30 | $44.03M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | $44.13M derived: sum of 2 quarters · filed 2022-11-09 | $44.55M 10-Q/A · filed 2022-11-09 | $134.00M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $516.00K 10-Q · filed 2022-08-02 | $89.97M derived: sum of 3 quarters · filed 2022-08-02 | $89.97M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $412.00K 10-Q · filed 2022-05-10 | $89.87M derived: sum of 2 quarters · filed 2022-05-10 | $89.87M derived: sum of 3 quarters · filed 2022-05-10 | $89.87M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $89.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $89.46M derived: sum of 2 quarters · filed 2022-03-01 | $89.46M derived: sum of 3 quarters · filed 2022-03-01 | $114.46M 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $25.00M 10-Q · filed 2021-11-08 | $217.77M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $25.00M 10-Q · filed 2021-08-10 | $217.77M derived: sum of 3 quarters · filed 2021-08-10 | $216.47M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $25.00M 10-Q · filed 2021-05-11 | $217.77M derived: sum of 2 quarters · filed 2021-05-11 | $216.47M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $192.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $191.47M derived: sum of 2 quarters · filed 2021-03-30 | $304.65M 10-K · filed 2021-03-30 | |
| 2019-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $111.88M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $113.17M 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $1.90M 10-K · filed 2020-03-19 | ||
| 2018-09-30 | $852.00K 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |